SEC Form 144 filed by Fate Therapeutics Inc.
$FATE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| Form 144 Filer Information |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144
NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 | |
FORM 144 |
144: Filer Information
| Filer CIK | 0001425738 |
| Filer CCC | XXXXXXXX |
| Is this a LIVE or TEST Filing? |  LIVE
 TEST
|
Submission Contact Information | |
| Name | |
| Phone | |
| E-Mail Address |
144: Issuer Information
| Name of Issuer | FATE THERAPEUTICS INC |
| SEC File Number | 001-36076 |
| Address of Issuer | 12278 Scripps Summit Drive San Diego CALIFORNIA 92131 |
| Phone | 858-875-1800 |
| Name of Person for Whose Account the Securities are To Be Sold | Redmile Group, LLC |
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account
the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given
as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales
for the account of the person filing this notice.
| |
| Relationship to Issuer | Director, 10% Stockholder |
144: Securities Information
| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | Number of Shares or Other Units Outstanding | Approximate Date of Sale | Name the Securities Exchange |
|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value(1) | J.P. Morgan Securities LLC 383 Madison Avenue New York � NY � 10179 | 341633 | 567110.78 | 113894333 | 12/20/2024 | Nasdaq |
Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment
of all or any part of the purchase price or other consideration therefor:
144: Securities To Be Sold
| Title of the Class | Date you Acquired | Nature of Acquisition Transaction | Name of Person from Whom Acquired | Is this a Gift? | Date Donor Acquired | Amount of Securities Acquired | Date of Payment | Nature of Payment * |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value(1) | 04/14/2023 | Private Placements from Stockholders | Redmile Affiliates(2) |  | 311523 | 04/14/2023 | Cash | |
| Common Stock, $0.001 par value(1) | 04/14/2023 | Acquisition of Class A Convertible Preferred Stock in Private Placements from Stockholders and Subsequent Cashless Conversion to Common Stock on 12/12/2024 | Class A Convertible Preferred Stock from Redmile Affiliates(2); Common Stock from Issuer | | 30110 | 04/14/2023 | Purchase of Class A Convertible Preferred Stock for Cash; Cashless Conversion to Common Stock |
* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note
thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made
in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.
Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.
144: Securities Sold During The Past 3 Months
| Nothing to Report |  |
144: Remarks and Signature
| Remarks | (1) The total number of shares of Common Stock that may be sold represents shares that may be sold on an aggregate basis by private investment vehicles managed by Redmile Group, LLC, as follows: Redmile Strategic Trading Sub, Ltd. - 35,528 shares; and Redmile Strategic Long Only Trading Sub, Ltd. - 306,105 shares. (2) "Redmile Affiliates" means certain private investment funds and sub-advised accounts for which Redmile Group, LLC serves as an investment manager/adviser. (3) Redmile Group, LLC is the investment manager of Redmile Strategic Trading Sub, Ltd. and Redmile Strategic Long Only Trading Sub, Ltd. |
| Date of Notice | 12/20/2024 |
ATTENTION: | |
| The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. | |
| Signature | /s/ Joshua Garcia, Chief Financial Officer, Redmile Group, LLC(3) |
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001) | |